Opinion

Video

Rethinking Uncomplicated UTI Treatment: Discussion of Aminoglycosides as an Alternative to Carbapenems

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-Spectrum β-lactamase-phenotype Gram-negative Enterobacterales,” including its objective, design, methodology, results, and key takeaways, and discusses how this data impacts the treatment of inpatient uncomplicated UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales

Video content above is prompted by the following:

  • Briefly describe the study “Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated Urinary Tract Infections Caused by Extended-spectrum β-lactamase-phenotype Gram-negative Enterobacterales.”
  • What was the objective of this study?
  • How was this study designed, and what methodology was used?
  • What results were presented?
  • Provide your key takeaways from this study. How does this data impact how you treat inpatient UTIs caused by extended-spectrum β-lactamase-producing Enterobacterales?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo